We prospectively compared 2 groups of multiple myeloma patients who had undergone autologous stem cell transplantation. The first group (group 1, n=30) received amifostine (740 mg/m2) whereas the second group (group 2, n= 36) did not receive this treatment, before melphalan infusion, as cytoprotectant for mucosal damage. Our results demonstrated that amifostine did not reduce the incidence or grading of mucositis, but it influenced the use of total parenteral nutrition and of opioid analgesic therapy.

Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma.

BACCARANI, MICHELE;TOSI, PATRIZIA;
2004

Abstract

We prospectively compared 2 groups of multiple myeloma patients who had undergone autologous stem cell transplantation. The first group (group 1, n=30) received amifostine (740 mg/m2) whereas the second group (group 2, n= 36) did not receive this treatment, before melphalan infusion, as cytoprotectant for mucosal damage. Our results demonstrated that amifostine did not reduce the incidence or grading of mucositis, but it influenced the use of total parenteral nutrition and of opioid analgesic therapy.
STOCCHI R; DAMIANI D; MASOLINI P; MICHELUTTI A; BACCARANI M.; TOSI P; FANIN R.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/5732
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact